In one operation, measurably yes: delayed wound healing was recorded in 18.5% of GLP-1 users having an abdominal panniculectomy against 7.5% of non-users, at P = 0.0066 [1]. The same cohort showed fewer seromas rather than more, so the fair summary is that the complication profile changes shape instead of getting uniformly worse. What the operation itself involves, and who ends up needing it, is covered in skin removal surgery after a GLP-1.
What the panniculectomy review found
A ten-year retrospective review compared 81 GLP-1 users against 292 non-users, all of them having the apron of skin and fat removed after major weight loss. Delayed wound healing was more than twice as common among the users. Seromas, which are the fluid collections under the skin that make up the commonest nuisance complication of this operation, were nearly three times less common at 4.9% against 14.0%, at P = 0.032.
Both differences survived multivariable adjustment. Infection, fat necrosis and hematoma showed no difference at all between the groups.
The baseline table complicates the wound finding specifically. GLP-1 users in this cohort had nearly double the rate of diabetes, at 55.6% against 29.5%, along with more hypertension and more chronic obstructive pulmonary disease. Diabetes is the textbook cause of delayed wound healing, and while the authors adjusted for confounders and the difference persisted, adjustment can only do so much with 81 exposed patients. 18.5% of 81 is fifteen people.
The seroma result is the more mechanistically interesting half and gets less attention. Seromas form in the dead space left when a large volume of tissue is removed, and somebody who already lost substantial weight on a drug before surgery may simply have less tissue to remove. That would make it a consequence of the weight loss rather than of the drug, which is a distinction this study cannot resolve.
Stopping earlier changed the rate
A second cohort split 80 lipoabdominoplasty patients four ways and matched them for age, body mass index and surgical technique [2]. Semaglutide continued to the day of surgery, stopped two weeks before, stopped four weeks before, or never taken. Thirty-day complications fell in a straight line: 45%, then 30%, then 10%, against 10% among those who had never taken it.
Wound dehiscence, infection and seroma were the events counted. Gastrointestinal intolerance and longer drain duration were also more common with ongoing use, and no patient in any group was readmitted or reoperated on. The wider question of when a prescriber asks for a pause is handled in whether you have to stop before surgery.
The nutritional mechanism behind it
A meta-analysis of 19 randomized trials found daily energy intake falling between 24.0% and 39.2% depending on the drug, with model-estimated daily deficits reaching 1,200 kcal [3]. Tirzepatide at 15 mg was associated with a loss of 1.60 kg of fat-free mass, which the authors put at 2.80% of body weight. A wound is built out of protein, and a patient eating a third less while rebuilding one is the plausible route from drug to delayed healing.
The same analysis found investigators recording malnutrition as an adverse event in 0.12% of participants while bloodwork flagged low lymphocyte counts in 2.90% on active therapy against 1.77% on placebo. Which laboratory values are worth checking is set out in the blood tests nobody quotes you a price for, and the protein question during rapid loss in how much protein you need.
What this changes before an operation
The practical step is to tell the surgical team what you are taking and when you last took it, and to expect a four-week gap to be asked for. A pause that cheap does not need a large trial behind it in the way an expensive or risky precaution would.
The cost that nobody quotes is the recovery. Slower healing means more dressing changes and more time away from work, and neither appears on a surgical estimate. A paused month can also break a prepaid plan term. What that pause costs is worked out in the prepay arithmetic, and the clotting side of the same perioperative question in what happens to clot risk after surgery.